Trial Profile
IFM 2008: Frontline Therapy in de Novo Multiple Myeloma Patients Under 65, (a Phase 2 Multicenter Trial).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Lenalidomide (Primary) ; Dexamethasone; Melphalan
- Indications Multiple myeloma
- Focus Therapeutic Use
- 22 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Sep 2010 New trial record